Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

By afschroeder • October 20, 2025

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Oct 19:101200JCO2502023. doi: 10.1200/JCO-25-02023. Epub ahead of print. PMID: 41109959.

Tags: binimetinib, BRAF, Encorafenib, Hematology/Oncology, Non-small cell lung cancer, Publications

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein[...]

Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium

Ho AS, Moyers JT, Attarian S, Banker R, Birkeland A, Chen MM, Coffey CS, Guo T, Haidar Y, Harris JP, Holsinger FC, Inman J, Jang[...]

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan[...]